Glaxosmithkline

Type
Internal restructuring
Country
United Kingdom
Region
North West (England); Cumbria; Westmorland and Furness
Location of affected unit(s)
Ulverston
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 - Manufacture of basic pharmaceutical products
190 - 191 jobs
Number of planned job losses
Job loss
Announcement Date
4 October 2018
Employment effect (start)
1 June 2019
Foreseen end date
31 December 2020

Description

Pharmaceutical company GlaxoSmithKline (GSK) has announced plans to cut 190 jobs from its operations in Ulverston, Cumbria. GSK announced in July 2017 that it would review operations at the site when it decided against going ahead with a previously planned investment. The business will continue to produce tablets at the site, but will no longer be concerned with the production of injectables. The company insisted that there is still a bright future in Cumbria, despite these plans to cut over half of its 345 jobs. The job losses will be phased with the first cuts taking place in June 2019 with a final end date of December 2020.

Citation

Eurofound (2018), Glaxosmithkline, Internal restructuring in United Kingdom, factsheet number 95727, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/95727.